Cardinal Health Inc. recalls RECOMBINATE and 1 more
- Published
- 13 Aug 2025
- Units affected
- 3 products
- Agency
- FDA
- Country
- United States
The hazard
CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
RECOMBINATE, [Antihemophilic Factor (Recombinant)], 5 mL vials, Rx Only, Takeda Pharmaceuticals USA, Cambridge, MA 02142, NDC: 00944-2843-01
Xolair (omalizumab injection), 75 mg/0.5 ml, Rx only, Genentech, Inc., South San Francisco, CA 94080, NDC 50242-214-55
Xolair (omalizumab injection), 150 mg/ml, 1 auto-injector, Rx only, Genentech, Inc, South San Francisco, CA 9408, NDC: 50242-215-55.
- Brand / company
- Cardinal Health Inc.
- Codes / lots
- Lot: TRB23802AC, Expires: 03/18/2026; TRA22804AA, Expires: 10/18/2025 | Lot: 3630004, Expires: 10/31/2025. | Lot: 3617756, Expires: 12/31/2025.
- Distribution
- Nationwide Within the U.S.
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 13 Aug 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.